The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 18, 2022

Filed:

Feb. 01, 2017
Applicant:

Cedars-sinai Medical Center, Los Angeles, CA (US);

Inventors:

Robert Barrett, Los Angeles, CA (US);

Clive Svendsen, Pacific Palisades, CA (US);

Stephan R. Targan, Santa Monica, CA (US);

Michael Workman, Santa Monica, CA (US);

Dhruv Sareen, Porter Ranch, CA (US);

Uthra Rajamani, Los Angeles, CA (US);

Assignee:

Cedars-Sinai Medical Center, Los Angeles, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/071 (2010.01); C12M 3/06 (2006.01); C12N 5/074 (2010.01); C12M 3/00 (2006.01); G01N 33/50 (2006.01); C12N 5/079 (2010.01);
U.S. Cl.
CPC ...
C12N 5/0679 (2013.01); C12M 21/08 (2013.01); C12M 23/16 (2013.01); C12N 5/0618 (2013.01); C12N 5/0696 (2013.01); G01N 33/5005 (2013.01); C12N 2501/11 (2013.01); C12N 2501/119 (2013.01); C12N 2501/13 (2013.01); C12N 2501/155 (2013.01); C12N 2501/16 (2013.01); C12N 2501/24 (2013.01); C12N 2501/25 (2013.01); C12N 2501/415 (2013.01); C12N 2501/998 (2013.01); C12N 2501/999 (2013.01); C12N 2506/45 (2013.01); C12N 2535/00 (2013.01);
Abstract

Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.


Find Patent Forward Citations

Loading…